Navigation Links
Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
Date:11/5/2007

mplication encountered during INTEGRILIN(R) therapy. The majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with INTEGRILIN(R) compared to placebo; INTEGRILIN(R) is associated with an increase in major and minor bleeding at the site of arterial sheath placement; special care should be employed to minimize the risk of bleeding among these patients; if bleeding cannot be controlled with pressure, infusion of INTEGRILIN(R) and concomitant heparin should be stopped immediately; because INTEGRILIN(R) inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostatic, including thrombolytics, oral anticoagulants, NSAIDs, and dipyridamole; use with other GP IIb-IIIa inhibitors should be avoided; INTEGRILIN(R) is cleared in part by the kidney and its plasma concentrations are doubled in patients with renal disease (CrCl <50 mL/min); therefore, the infusion dose of INTEGRILIN(R) needs to be reduced to 1mcg/kg/min in these patients; INTEGRILIN(R) is contraindicated in patients who are dependent upon renal dialysis (please see dosing guidelines); caution should be exercised when administering INTEGRILIN(R) to patients with a platelet count <100,000/mm3.

Full prescribing information for INTEGRILIN(R) is available at http://www.integrilin.com.

About Schering-Plough

Schering-Plough Corporation is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 33,500 people around the world. Th
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015   Decision Resources ... differences in dialysis patient management in the U.S. ... submitted by U.S. and EU5 nephrologists from approximately ... binders are the most commonly used renal medications ... iron differs considerably between the two regions.      ...
(Date:7/7/2015)... , July 7, 2015 The ... USD 1,197.7 million by 2020, growing at an estimated CAGR ... study by Grand View Research, Inc. Introduction of innovative technologies ... with growing awareness levels pertaining to the advantages of breast ... next six years. In addition, presence of untapped growth opportunities ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... SAN RAFAEL, Calif. , Aug. 4 To ... companies have selected New Momentum, the leading SaaS-based anti-counterfeiting solution.  Both ... and shut down violators, their New Momentum solution will play a ... , , ...
... Aug. 4 Cytel Inc., premier provider of adaptive clinical trial ... software package for adaptive dose-finding studies based on frequentist or Bayesian methods. , ... The FDA,s recently issued adaptive trial guidelines ... level.  , , , ...
Cached Medicine Technology:Two More Global Pharmaceutical Companies Choose New Momentum to Stop Counterfeits 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 3
(Date:7/7/2015)... ... July 07, 2015 , ... The plastic surgery ... on the cosmetic surgery industry with its commitment, teamwork, and dedication — all ... medical provider is committed to patient safety, world-class results, and compassionate care. With ...
(Date:7/7/2015)... New York, NY (PRWEB) , ... July 07, 2015 , ... ... only thing that can help pass those long, stressful days at work is knowing ... vacations aren’t always as laid back and stress free as imagined. Planning for a ...
(Date:7/7/2015)... ... July 07, 2015 , ... The United States Centers for Disease Control and ... and the Multicultural AIDS Coalition $3.78 million for a five-year HIV prevention ... men (MSM) and transgender women, the groups at highest risk of HIV infection ...
(Date:7/7/2015)... ... July 07, 2015 , ... SC&H Group, a leading audit, tax, ... give back to the community through company-wide volunteering efforts. , On an annual basis, ... day to assisting those in need throughout Baltimore and Washington D.C. , ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency Foundation ... patient community using its IDF ePHR, an electronic personal health record powered by ... to easily track their health information, including symptoms, diagnoses, medications, infusions and other ...
Breaking Medicine News(10 mins):Health News:Top Plastic Surgery Provider in Brazil Joins VisitandCare.com 2Health News:Top Plastic Surgery Provider in Brazil Joins VisitandCare.com 3Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3
... a web based weight loss programme can be doubly benefited, ... finding of a research study appearing in the August 14 ... The Miriam Hospital and University of North Carolina. ... essential that we identify and improve on the components of ...
... testosterone, which is the male sex hormone linked with virility ... die early. ,US scientists had studied the relationship ... over 40. Reporting their findings in the Archives of Internal ... an 88% increased risk of death as compared to men ...
... using genetic material ,called targeting RNA, to enter cancer ... stop the expression of a protein that keeps the ... cells ,unharmed. ,The drug, developed at Duke ... called In tests in mice with prostate cancer, the ...
... early delivery of twins, much in contrast with the delivery ... likelihood of risks if twins are delivered after 40 weeks, ... an early delivery. ,A University of Ottawa, ... deliver twins was between 38 and 39 weeks. This does ...
... that even in young neurons it is the survival of ... off// depends on its ability to establish connections with other ... Fred H. Gage, Ph.D., a professor in the Gene Expression ... on Age-Related Neurodegenerative Diseases. It says that a subunit of ...
... Age may be more related to reactions to stress ... person’s chronological age, say leading researchers in the fields ... good bet if stress can be moderated along with ... presented at the 114th Annual Convention of the American ...
Cached Medicine News:Health News:Weight loss given a thrust with e-counselling 2Health News:Low Testosterone Linked With Early Death 2Health News:Fittest Of Newborn Neurons Survive 2Health News:Fittest Of Newborn Neurons Survive 3Health News:Wear and Tear of Stress: The Psychoneurobiology of Aging 2Health News:Wear and Tear of Stress: The Psychoneurobiology of Aging 3
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: